BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, an oral inhibitor of the anti‐apoptotic molecule B‐cell lymphoma (BCL‐2), has shown great efficacy in chronic lymphocytic leukemia (CLL) (Roberts et al. 2016; Seymour et al. 2018; Stilgenbauer et al. 2016).